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Precision medicine (PM) requires the delivery of individually adapted medical care based
on the genetic characteristics of each patient and his/her tumor.The last decade witnessed
the development of high-throughput technologies such as microarrays and next-generation
sequencing which paved the way to PM in the ﬁeld of oncology. While the cost of
these technologies decreases, we are facing an exponential increase in the amount of
data produced. Our ability to use this information in daily practice relies strongly on
the availability of an efﬁcient bioinformatics system that assists in the translation of
knowledge from the bench towards molecular targeting and diagnosis. Clinical trials and
routine diagnoses constitute different approaches, both requiring a strong bioinformatics
environment capable of (i) warranting the integration and the traceability of data, (ii)
ensuring the correct processing and analyses of genomic data, and (iii) applying well-
deﬁned and reproducible procedures for workﬂow management and decision-making. To
address the issues, a seamless information system was developed at Institut Curie which
facilitates the data integration and tracks in real-time the processing of individual samples.
Moreover, computational pipelines were developed to identify reliably genomic alterations
and mutations from the molecular proﬁles of each patient. After a rigorous quality control,
a meaningful report is delivered to the clinicians and biologists for the therapeutic decision.
The complete bioinformatics environment and the key points of its implementation are
presented in the context of the SHIVA clinical trial, a multicentric randomized phase II
trial comparing targeted therapy based on tumor molecular proﬁling versus conventional
therapy in patientswith refractory cancer.The numerous challenges faced in practice during
the setting up and the conduct of this trial are discussed as an illustration of PM application.
Keywords: precision medicine, clinical trial, bioinformatics, sequencing, oncology, SHIVA
INTRODUCTION
ERA OF PRECISION MEDICINE
Though physicians have always considered the individual charac-
teristics of each of their patients, the term personalized medicine
appeared recently to account for our new abilities to characterize
each person biologically with genomic analysis, and to use this
information to guide medical decision-making and deliver the
best treatment to each patient. This concept is also referred to as
genomic medicine, and other terms such as stratiﬁed medicine
or targeted medicine are sometimes used interchangeably. A few
years ago, the concept of P4 medicine was introduced with the
idea of managing the patient’s health instead of the patient’s dis-
ease (Hood and Friend, 2011). As a matter of fact, the practice
of medicine today is mainly reactive, i.e., the physician treats the
patient’s disease and little is done to prevent the occurrence of the
disease. The P4 medicine considers a model of healthcare that is
predictive (considering the genetic background of the individual
and his/her environment), preventive (adapting lifestyle, taking
prophylactic drugs), personalized (tailoring the treatment to the
individual’s unique features, such as the patient’s genetic back-
ground, the tumor’s genetic and epigenetic landscape, his/her life
environment) and participatory (many options about healthcare
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which require in-depth exchanges between the individual and
his/her physician). P4 medicine therefore extends the concept of
personalized medicine.
The term precision medicine (PM) is also frequently encoun-
tered in the literature to denote similar ideas, and generally refers
to delivering the right drug at the right time to the right patient,
by targeting speciﬁcally the molecular events that are responsible
for the disease. We will use in this article the terminology PM
deﬁned as a customization of healthcare that takes into account
individual differences among patients from prevention, diagnosis,
prognosis, choice of the treatment and follow-up. PM combines
the knowledge of the patient’s characteristicswith traditionalmed-
ical records and environmental information to optimize health.
PM does not only rely on genomic medicine but also integrates
any other relevant information such as non-genomic biological
data, clinical data, environmental parameters and the patient’s
lifestyle.
PM IN ONCOLOGY
In a special issue, the Journal of Clinical Oncology has focused
on PM in oncology (Garraway et al., 2013) showing that this
new era of medicine offers new perspectives to cure cancer. PM
also raises numerous challenges including biobanking, bioinfor-
matics and legal issues (Garraway et al., 2013; Meric-Bernstam
et al., 2013; Overby and Tarczy-Hornoch, 2013; Suh et al., 2013).
The intrinsic complexity of cancer and the variety of its forms
(each tumor being genetically unique) designate this pathol-
ogy as a prime target for PM approaches. Cancer is a disease
caused by the accumulation of mutations occurring in critical
genes (oncogenes and tumor-suppressor genes) and resulting in
the alteration of key molecular pathways. Due to the genetic
nature of cancer, the oncology research has largely beneﬁted from
the advances in high-throughput genomics technologies in order
to decipher the molecular alterations involved in the tumori-
genesis on one hand, and to help the clinician to tailor the
therapy on the other (Tamborero et al., 2013). Molecular pro-
ﬁling based on genomics information from the tumoral DNA
and constitutional DNA offers new insights into the predic-
tion of the disease progression and the response to treatment
for each individual patient. These approaches are based in par-
ticular on two dominant concepts: oncogene addiction and
synthetic lethality. The ﬁrst one, oncogene addiction, stipulates
that some tumors rely on one particular oncogene for their sur-
vival and progression, and inhibiting this gene would therefore
stop tumor growth; this is the magic bullet idea introduced by
Paul Ehrlich in 1900. The second one, synthetic lethality, refers
to the observation that the inactivation of a pair (or more) of
genes might be lethal, whereas individual inactivation of any
of these genes would not kill the cell. It offers an opportunity
to selectively kill cancer cells, if they already present gene inac-
tivation for one gene of the synthetic lethal pair, by targeting
the second gene of the pair. A famous example is the syn-
thetic lethality of BRCA and PARP genes, which is exploited by
using PARP inhibitors for treating BRCA deﬁcient breast cancer
tumors. Both oncogene addiction and synthetic lethality are typ-
ical situations where targeted therapy should be the solution of
choice.
The identiﬁcation of genomic alterations used as biomark-
ers along with the emergence of molecularly targeted agents
(MTAs) such as tyrosine-kinase inhibitors have promoted the
development of PM in oncology. MTAs have proven their efﬁ-
cacy in some cancer subtypes and they provide new opportu-
nities to treat the disease (see Dienstmann et al., 2013, for a
review). The ﬁrst MTA has been trastuzumab, which is a mon-
oclonal antibody targeting the ERBB2 receptor. This gene is
ampliﬁed in 15–20% of patients with breast adenocarcinoma.
Treating patients with locally advanced disease with trastuzumab
for a year decreases by 50% the risk of recurrence (Piccart-
Gebhart et al., 2005). Targeting the BCR/ABL fusion gene (i.e.,
the Philadelphia chromosome) with another MTA, imatinib, in
patients with chronic myelogenous leukemia has dramatically
improved their outcome (Druker et al., 2001). BRAF(V600E)
mutation is frequently associated with melanoma, where it
seems to play a critical role in the malignancy process and
can be effectively treated using vemurafenib (Flaherty et al.,
2010). BRAF(V600E) mutation has been also identiﬁed in mul-
tiple forms of advanced cancers such as colorectal or thyroid
cancer (Cantwell-Dorris et al., 2011). It is generally accepted
today that using MTA has great potential in the treatment of
many types of cancer. Around 40 MTAs have been approved
to date for the treatment of cancer and the development of
new inhibitors is in progress. Developing new MTAs imply
also to decipher new biomarkers among the large number of
genomic alterations observed in tumors (mutations, ampliﬁ-
cations, deletions, translocations, fusions and other structural
variants). A large number of genomic alterations are passen-
gers while very few are drivers. A subset of these drivers
are actionable, i.e., have signiﬁcant diagnosis, prognosis, or
therapeutic implications in cancer, and a subset may also be
druggable, i.e., targets for therapeutic development (Dancey
et al., 2012). Classifying these genomic alterations into action-
able and/or druggable is difﬁcult and high-throughput screening
techniques might help this classiﬁcation. The possibility to search
within each tumor the actionable/druggable alteration using high-
throughput technologies opens the way to PM in the ﬁeld of
oncology.
HIGH-THROUGHPUT SCREENING TECHNOLOGIES FOR PM
During the last two decades, the advent of high-throughput
technologies has allowed the genome-wide characterization of
molecular proﬁles in tumors. Among the different techniques,
the gene-expression microarrays have been widely used so far
in particular to build signatures for diagnostic and prognostic
purposes. These gene signatures are now proposed as clinical
tools for some types of breast cancer, for example Agendia’s 70-
gene Agilent-based MammaPrint®, i.e., the Amsterdam Signature
(van’t Veer et al., 2002; van de Vijver et al., 2002), Veridex’s 76-
gene signature, i.e., the Rotterdam Signature (Wang et al., 2005;
Foekens et al., 2006), Genomic Health’s 21-gene RT-PCR-based
Oncotype DXTM (Cobleigh et al., 2005; Hornberger et al., 2005)
and a 41-gene expression set (Ahr et al., 2001; Molecular, Ahr
et al., 2002). Ten years ago, next-generation sequencing (NGS)
technology appeared. It has evolved so quickly that it is pos-
sible today to sequence a genome for a few thousand dollars
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within a few days. Of note, the sequencing of the ﬁrst human
genome costed around 3 billion dollars and took more than
10 years to be completed in 2003. The ability to simultaneously
sequence millions of short nucleic acid fragments in parallel in
a very short time and at very competitive costs (Sboner et al.,
2011) makes NGS a major tool in oncology (Tran et al., 2012).
NGS will very likely replace microarrays in a near future both
for research and clinical applications. The current NGS tech-
niques allow the proﬁling of the transcriptome (RNA-seq), the
genome (DNA-seq, exome-seq), the epigenome (bisulﬁte-seq),
the identiﬁcation of DNA-protein interactions (ChIP-seq) and
the reconstruction of chromosome architecture (Hi-C). While
some sequencing platforms are very suitable for research pur-
poses, the long duration of runs as well as the cost of these
instruments are clearly incompatible with a real-time applica-
tion for clinical use (e.g., the HiSeq sequencer from Illumina
which tends to become the reference for very high-throughput
sequencing, requires approximately 11 days per instrument and
per run to generate data). In response to these concerns, bench-
top sequencers were introduced such as the MiSeqDxTM from
Illumina or the Ion TorrentTM PGM from Life Technologies.
Benchtop sequencers allow the sequencing of a few megabases
in a couple of hours with a very high depth of coverage. Their
relatively low cost and rapid turnaround timemake themvery suit-
able for clinical applications. In November 2013, the MiSeqDxTM
was the ﬁrst sequencer obtaining clearance from the Food and
Drug Administration for clinical use as this platform demon-
strated its precision and reproducibility across instruments, users,
days and reagent lots (Collins and Hamburg, 2013). Benchtop
sequencers make it possible to sequence rapidly fractions of the
genome (target-seq) like the coding regions or a subset of known
genes or mutation hotspots. The target-seq offers the possibility
to screen several hundred mutation hotspots located in tumor-
suppressor genes and oncogenes using dedicated cancer panel kits.
Thus, the target-seq techniques offer new opportunities for diag-
nosis andmany laboratories are shifting fromSanger sequencing to
NGS platforms in order to meet challenges in terms of through-
put and turnaround time. As an example recent advances have
been made in the screening of the BRCA1 and BRCA2 genes and
the detection of germline mutation related to an increased risk
of developing breast cancer (Bosdet et al., 2013; Tarabeux et al.,
2013).
FRAMEWORK FOR PM IN ONCOLOGY
Precision medicine requires a strong interdisciplinary collabo-
ration between several stakeholders covering a large continuum
of expertise ranging from medical, clinical, biological, trans-
lational, technical, and biotechnological know-hows. Figure 1
illustrates the different practitioners involved in the complex
process, describes the data workﬂow starting from and com-
ing back to the patient in order to tailor the therapy and shows
the informatics and bioinformatics infrastructure supporting the
workﬂow. To build the therapeutic decision, the most exhaus-
tive data ranging from clinical to biological, environmental and
family information (e.g., description of the tumor histology,
list of previous treatments, family history, etc.) needs to be
collected along a complex healthcare pathway. As the disease
evolves, new experiments such as high-throughput screens (with
microarray or NGS technologies for example) or biomarkers
detection by immunohistochemistry (IHC) have to be performed
to measure relevant biological information required to choose
the best therapy. During the process, physicians (including dif-
ferent specialists such as surgeons, pathologists, radiation and
medical oncologists, etc.), biologists, pharmacists, bioinformati-
cians, computational biologists, biostatisticians, informaticians,
biobank managers, biotechnological platform managers, clinical
research associates, and the technical staff will offer their exper-
tise for the beneﬁt of the patient. Different actors and cultures
and a variety of miscellaneous constraints, including meeting
the deadlines for results delivery, render the application of PM
in daily clinical practice extremely challenging. Organizational
aspects are therefore essential for the success of PM (Veltman
et al., 2013). Downing et al. (2009) mentioned the importance
of Electronic Health Record (EHR) and Clinical Decision Sup-
port (CDS) for care delivery due to the acceleration of knowledge
discovery and its impact on the increasing number of possible
clinical decisions. Development in CDS is required to han-
dle the large heterogeneity of data and their complexity. The
authors also pinpoint the fact that PM strongly depends on
our ability to collect, disseminate and process complex infor-
mation. Indeed, every stakeholder produces information during
the healthcare pathway at different time points and in different
places. The overall information needs to be gathered, integrated
and summarized in a digest report to facilitate the therapeutic
decision-making.
NEED FOR BIOINFORMATICS SOLUTIONS TO SUPPORT PM
The availability of high-throughput technologies dedicated to
clinical applications makes it very attractive for cancer centers
to use these new tools on a daily basis. However, establishing
such a clinical facility is not a trivial task due to the aforemen-
tioned complexity of PM framework alongwith the overwhelming
amount of data. Indeed, the ﬁeld of oncology has entered the
so-called big data era as the particle physics did several years
ago. From the big data 4 V’s perspective, data integration issue
(i.e., merging heterogeneous data in a seamless information
system) in oncology can be formulated as follows: a large Vol-
ume of patients’ data is disseminated across a large Variety of
databases which increase in size at a huge Velocity. In order
to extract most of the hidden Value from these data we must
face challenges at: (i) the technical level to develop a power-
ful computational architecture (software / hardware), (ii) the
organizational and management levels to deﬁne the procedures
to collect data with highest conﬁdence, quality and traceability,
and (iii) the scientiﬁc level to create sophisticated mathemati-
cal models to predict the evolution of the disease and risks to
the patient. Obviously, an efﬁcient informatics and bioinformat-
ics architecture is deﬁnitely needed to support PM in order to
record, manage and analyze all the information collected. The
architecture must also permit the query and the easy retrieval of
any data that might be useful for therapeutic decision in real-
time thus allowing clinicians to propose the tailored therapy
to the patient in the shortest delay. Therefore, bioinformatics
is among the most important bottlenecks towards the routine
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FIGURE 1 | Framework for PM in oncology. The left part describes the
workﬂow and processes required for the decision-making from patient
consultation to the therapeutic decision. The middle part focuses on the
informatics and bioinformatics architecture required to support the different
steps of the workﬂow. The right part indicates the different experts involved
in each process.
application of PM and several challenges need to be faced to
make it a reality (Fernald et al., 2011). First, the development
of a seamless information system allowing data integration, data
traceability, and knowledge sharing across the different stake-
holders is mandatory. Second, bioinformatics pipelines need to
be developed in order to provide relevant biological informa-
tion from the high-throughput molecular proﬁles of the patient.
Third, the architecture must warrant the reproducibility of the
results.
If many recent publications point out the key role of the
bioinformatics for PM today (see Simon and Roychowdhury,
2013 for a review), clinical trials usually do not detail the
complete bioinformatics environment used in practice to assess
the quality and the traceability of the generated data. Differ-
ent software platforms such as transMART (Athey et al., 2013),
G-DOC (Madhavan et al., 2011) or the cBio Cancer Genomics
Portal (Cerami et al., 2012) have been recently developed to
promote the data sharing and analysis of genomics data in
translational research. Canuel et al. (2014) reviewed the differ-
ent solutions available and compared their functionalities. One
of the most interesting features of these platforms relies on
their analytical functionalities. They provide ready-to-use tools
through user-friendly interface offering interesting functionali-
ties for data queries and user analysis. However, these different
solutions do not address essential aspects which are offered by
our system: ﬁrst, often they handle a speciﬁc type of data;
second they do not cover management and traceability of the
data in real-time as long as they are generated by the different
stakeholders; third they do not provide clinicians with a mean-
ingful digest of the analyses, which they need to take clinical
decisions.
In the next section, we will focus on the bioinformatics solu-
tions implemented in order to tackle these challenges in the Institut
Curie Bioinformatics platform in the context of the SHIVA clinical
trial (Le Tourneau et al., 2012) initiated in October 2012 at Institut
Curie (Paris, France). This trial provides a concrete and practical
application of a PM project. First, we will describe the design of
the SHIVA clinical trial. Second, the seamless information system
we have implemented to manage data along with the bioinfor-
matics pipelines used to deliver the results for the therapeutic
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decision will be presented. Finally, the ongoing challenges will be
listed.
DESIGN OF THE SHIVA CLINICAL TRIAL
SHIVA is a randomized proof-of-concept phase II trial com-
paring molecularly targeted therapy based on tumor molecular
proﬁling versus conventional therapy in patients with refractory
cancer1 (Figure 2A; Le Tourneau et al., 2012). Randomized trials
in oncology are usually performed in a homogeneous population
of patients with a speciﬁc tumor type and in a speciﬁc setting. In
contrast, the goal of the SHIVA clinical trial is to bring the proof-
of-concept that the prescription of molecularly targeted therapies
1http://clinicaltrials.gov/show/NCT01771458
FIGURE 2 |The SHIVA clinical trial. (A) Rationale of the trial. The SHIVA trial
aims at determining whether the prescription of molecularly targeted
therapies based on tumor molecular abnormalities, independently of primary
tumor location and histology, would improve the outcome of cancer patients.
(B) Design of trial (adapted from LeTourneau et al., 2012). The SHIVA clinical
trial involves many different actors from the patient inclusion to the
therapeutic decision. The whole process requires less than four weeks
including 4 days for the bioinformatics treatment.
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based on tumor molecular abnormalities, independently of pri-
mary tumor location and histology, would improve the outcome
of cancer patients. Therefore, all tumor types are allowed in the
trial (n.b. no more than 20% of patients with the same primary
tumor location will be randomized). Both DNA copy number
alterations and mutations in a subset of 76 genes are considered
for the decision-making. These genes cover in particular three
main signaling pathways: (1) the hormone receptors pathway, (2)
the PI3K/AKT/mTOR pathway, and (3) the MAP kinase pathway.
They include predictive biomarkers of efﬁcacy of the MTAs as
well as known biomarkers of resistance (e.g., KRAS). These pre-
dictive biomarkers had either been validated in the clinic (e.g.,
ERBB2 ampliﬁcation for anti-ERBB2 therapy, Piccart-Gebhart
et al., 2005) or been supported by strong preclinical study (e.g.,
PI3KCA mutations for mTOR inhibitors, see Carew et al., 2011,
for a review). Of note, not all of the 76 genes are of interest for the
SHIVA trial but the whole panel includes mutations that might be
of interest for non-randomized patients who may be eligible for
clinical trials based on not yet approved MTAs. For each patient, a
biopsy from themetastasis is performed and themolecular proﬁles
are assessed using both the Cytoscan HD technology (Affymetrix)
for the detection of DNA copy number alterations and loss of
heterozygosity (LOH), and the Ion TorrentTM PGM sequencing
technology (Life Technology) for the detection of somatic muta-
tions. IHC is used for the assessment of hormone receptor status,
including estrogen, progesterone and androgen receptors, as well
as for the validation of focal gene ampliﬁcations detected with
Cytoscan HD in the following genes: ALK, BRAF, EGFR, ERBB2,
KIT, MET, PDGFRA, PDGFRB and PTEN. Only samples which
contain more than 30% of tumor cells are processed to control
at best sample heterogeneity. Patients from seven hospitals in
France can be included in the study. The establishment of the
molecular proﬁles follows the process and the timelines described
in Figure 2B. All the bioinformatics steps including data man-
agement and integration, molecular proﬁle analyses and data
coherence checking, are centralized at the Institut Curie bioin-
formatics platform. This centralization permits the analysis of the
molecular data from the different hospitals using the same param-
eters therefore ensuring the reproducibility of results. The whole
process was set up in real-time in order to have less than four
weeks elapsed between the biopsy and the randomization, includ-
ing 4 days for the bioinformatics treatment (Figure 2B). Thus,
this trial represents a concrete application of PM. It highlights
the real challenges and difﬁculties about the feasibility of such
project in real-time. A committee of expert named the Molecular
Biology Board (MBB) has been appointed. It consists of biolo-
gists, bioinformaticians and medical oncologists of each hospital.
The MBB meets each week to decide what the best therapy is
for each patient. Based on its scientiﬁc expertise and a literature
review, the MBB has deﬁned a set of rules taking into account
the relevant molecular abnormalities identiﬁed in the tumor to
decide which MTAs to choose (among a list of 11 drugs) to
treat the patient. MTAs allowed in trial are only drugs that are
approved for clinical use in France. In the next section, we will
describe the bioinformatics solutions we have developed at Insti-
tut Curie to manage the data workﬂow for the SHIVA clinical
trial.
BIOINFORMATICS ENVIRONMENT FOR THE SHIVA CLINICAL
TRIAL
SEAMLESS INFORMATION SYSTEM
Precision medicine relies on a tight connection between many
different stakeholders. As the choice of the therapy is based on
a combination of different information levels including clini-
cal data, high-throughput proﬁles (somatic mutations and DNA
copy number alterations) and IHC data, all this information
related to a given patient needs to be gathered in a seamless
information system. Data integration is deﬁnitely required and
bioinformatics plays a central role in setting up this infrastructure.
To tackle this challenge, we have developed a seamless infor-
mation system named KDI (Knowledge and Data Integration)
described in Figure 3. The KDI system ensures information shar-
ing, cross-software interoperability, automatic data extraction,
and secure data transfer. In the context of the SHIVA clinical
trial, high-throughput and IHC data are sent by the different
biotechnological platforms to the bioinformatics platform using
standardized procedures for transfer and synchronization. Data
are then integrated into the KDI system within ad-hoc repos-
itories and databases. Metadata describing the data are stored
in the KDI core database such as the patient identiﬁer, the type
of data (e.g., mutation screening, clinical data, DNA copy num-
ber proﬁle) and the technology used (e.g., Affymetrix microarray,
Ion TorrentTM PGM sequencing). Each type of data is then pro-
cessed by dedicated bioinformatics pipelines in order to extract
the relevant biological information such as the list of muta-
tions and the list of ampliﬁcations/deletions. Therefore, the KDI
core database acts as a hub allowing referencing all data through
the use of web services. The KDI core database knows exhaus-
tively which data is available for a given patient and where the
raw and processed data are physically stored. It thus offers the
possibility for clinicians to make queries through a web applica-
tion and to extract the list of available information for a given
patient. In addition, the system is also used to manage and per-
form automatic integrative analysis required for the therapeutic
decision.
From a technical point of view, the KDI system consists of dif-
ferent modules dedicated to the storage, processing, analysis and
visualization of each type of data (clinical, biological, microar-
ray, NGS, etc.). High modularity associated with an efﬁcient
interoperability makes our system able to retrieve any relevant
information. To facilitate the developments of these modules, we
have retained a classical n-tiers architecture implemented with
the JAVA/J2EE language. The core of each module of the KDI
system can be presented as the association of different layers
(Figure 3B).
Data layer
Data are stored in a relational database using the Entity-Attribute-
Value (EAV) pattern. This conceptual modeling provides a data
model plasticity required to handle the heterogeneity and the
scalability of the variables of interest. Therefore, with EAV model-
ing, same concepts managed by different projects (with speciﬁc
requirements by project) can be stored in a unique database
without any modiﬁcation of the data model. MySQL has been
chosen as database provider for all web applications of the system.
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FIGURE 3 | Knowledge and data integration system. (A) Integration of
heterogeneous data requires a seamless information system with high
scalability, plasticity, reliability and interoperability. (1) The samples are ﬁrst
collected for a given patient. (2) The samples are then processed by the
technological platforms (NGS, microarrays, immunochemistry, etc.) (3) Raw
data are analyzed using dedicated bioinformatics pipelines. Results are stored
in dedicated applications. (4) Sample data and the corresponding patient are
referenced in the KDI core system. (5) Advanced research functionality enable
multiple data queries. (6) Speciﬁc bioinformatics pipelines generate new
integrative knowledge from heterogeneous sources of data. (B)Technical
view of web applications: web applications are based on n-tiers architecture,
developed with J2EE technologies.
Complementary solutions such as NoSQL databases are currently
evaluated for particular requirements (ontologies storage, speciﬁc
queries, etc.).
Data access layer
Data access is supported by the DAO (DataAccess Object) pattern.
By using HibernateDaoSupport superclass provided by Spring
Framework, we promote the standardization of database access
for all standard queries (ﬁndAll, ﬁndById, save, delete). More-
over,Hibernate mapping through JPA annotations associated with
use of Hibernate Criteria provides a homogeneous frame for this
critical layer. Database sessions and transactional aspects are also
delegated to Spring Framework.
Business layer
Business core of our web applications has two main objectives:
(i) provide structured data for presentation layer, and (ii) make
data available for remote and secured access by other applica-
tions and technical users. Standard services are developed using
core functionalities of Spring framework (Aspect-Oriented Pro-
gramming - AOP, Inversion of Control - IoC, JavaBeans Factory).
Web services are published (server side) and invoked (client side)
through Apache CXF framework. To respect Web Services Secu-
rity (WS-Security) standards, we use the Apache WSS4J project
provided by CXF (with interceptors chain process) to set up a
username token authentication on each web application in the
system.
Front-end layer
Presentation layer is based on JSF (Java Server Faces) which is a
component oriented framework for building user interfaces for
web applications. To enrich the basic component set provided
by JSF, we use additional component libraries such as Apache
Trinidad and Primefaces. By this systematic approach for each
user interface, we aim to build a visual identity, ergonomic, eas-
ily usable, for the whole information system. All data available
within KDI can be browsed and retrieved from a user-friendly
bioinformatics web portal.
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Client layer
This layer represents the web browser through which end-users
access KDI system.
DNA COPY NUMBER ANALYSIS PIPELINE
The use of the Affymetrix CytoscanHD microarray allows both
the detection of DNA copy number alterations and the loss
of heterozygosity events. The analysis workﬂow is presented in
Figure 4A. Raw data are normalized with the Affymetrix Power
Tools software package2. Then, the log R ratio is segmented
2http://www.affymetrix.com
in order to detect breakpoints and assign copy number status
using Colibri (Rigaill, 2010) and GLAD (Hupé et al., 2004) soft-
ware. A similar process is applied on the allele difference proﬁle
using the GAP software (Popova et al., 2009). Both proﬁles (DNA
copy number and LOH) allow the estimation of absolute copy
number for each probe taking into account the sample cellu-
larity and tumor ploidy estimated by the GAP algorithm. Each
gene status (normal, gained, ampliﬁed, lost, deleted, loss of
heterozygosity) can then be assessed. Copy number alterations
are deﬁned as follows: deletion = 0 copy, loss = 1 copy, nor-
mal = 2 copies, gain = 3, 4 or 5 copies and ampliﬁcation ≥ 6
copies for diploid tumor, and deletion = 0 copy, loss = 1 or
FIGURE 4 | Bioinformatics analysis pipelines. (A) DNA copy number
analysis pipeline. The DNA copy number signal is segmented and called to
detect genomic alterations (deletion, loss, normal, gain and ampliﬁcation) and
loss of heterozygosity taking into account the sample cellularity. Focal gains
or ampliﬁcations are then identiﬁed as potential druggable regions.
(B) Mutation analysis pipeline. The sequenced reads are aligned on the
human reference genome, and centered on the targeted genomic regions.
Single nucleotide variations (SNVs) and insertion/deletion (indels) are then
called. The ﬁltered variations can then be annotated using additional
databases in order to lead to a ﬁnal list of potential druggable variants.
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2 copies, normal = 3 or 4 copies, gain = 5 or 6 copies and
ampliﬁcation ≥ 7 copies for tetraploid tumors. Additional steps
in the analysis are performed to distinguish between large scale
events such as chromosome arm gain and focal events target-
ing single oncogene or tumor-suppressor gene. Focal gains and
ampliﬁcations are deﬁned as genomic alterations with a size less
than 10 Mb, and a copy number greater than the surrounding
regions. In order to check whether a focal gain or an ampliﬁcation
of a size between 1 and 10 Mb induce a protein overexpres-
sion, a validation using IHC is performed. A report with the
list of genes to be validated by IHC is automatically sent to the
pathologists.
MUTATION ANALYSIS PIPELINE
The bioinformatics pipeline presented in the Figure 4B was
applied to detect somatic mutations from the Ion TorrentTM PGM
sequencer using the AmpliseqTM cancer panel. Ion TorrentTM
PGM raw reads are aligned on the reference human genome hg19
using the TMAP aligner (v0.3.7 Life Technologies). The best map-
ping score for each read is used to detect misalignment. The
standalone package of the Torrent Variant Caller (v2.2 Life Tech-
nologies) is then used to call variants (SNVs and indels) from the
mapped reads. In the context of clinical trial, variants have to be
ﬁltered to promote a high speciﬁcity, in order to avoid any false
positive mutations. Thus, detected variants are ﬁltered accord-
ing to their frequency (≥4% for SNVs and 5% for indels), strand
ratio (≥0.2), and reads coverage (≥30X for SNVs and 100X for
indels). In addition, SNVs and mainly insertions and deletions
detected in the context of a repeated region or a homopoly-
mer are double checked. Homopolymer and repeated regions are
prone to contain recurrent false positive, because of the limita-
tion of the Ion TorrentTM PGM technology. In most cases, the
variant is discarded if also detected in other patients from the
same sequencing run. Otherwise, variations speciﬁc to a sam-
ple, even within a repeat context, are reported. To facilitate the
interpretation of individual patient data for clinical trials, the
ﬁltered list of variants is then annotated using the ANNOVAR
software (Wang et al., 2010). Common polymorphisms found on
more than 1% of the ESP or 1K Genome project population as
well as recurrent and neutral variants on hotspots are reported.
These variants do not present any therapeutic interest but are
good internal controls to ensure the quality of the sequencing
data. The Catalog of Somatic Mutation in Cancer (COSMIC) is
used to annotate the mutations detected at a hotspot position.
Non targeted mutations in genes covered by the panel, being non
polymorphic nonsense, missense or indels are also reported, even
if it may be difﬁcult to know whether the alteration is involved in
deregulating a particular pathway and whether it is clinically rel-
evant. However, more stringent frequency ﬁltering are applied for
these cases (frequency ≥10% for SNVs and 15% for indels) lead-
ing to a higher speciﬁcity. Then, relevant mutations and variations
are visualized using the IGV browser (v.2.0.35, Thorvaldsdóttir
et al., 2013). The visualization remains an important step to assess
the overall quality of the variant call, by taking into account the
reads coverage, the error rate in the ﬂanking region, the mutation
position across the targeted region and across reads supporting
them.
INTEGRATIVE ANALYSIS: THE REPORT FOR THE MOLECULAR BIOLOGY
BOARD
The last step of the bioinformatics workﬂow is the production a
technical report for the MBB. This task is crucial and must be
complete and precise on one hand, and summarized on the other
to allow a quick decision of the board. To answer this need, a
report is generated for each patient. This report ﬁrst presents the
clinical information of the patient and the overall molecular pro-
ﬁles per gene, with the DNA copy number alterations, LOH status,
and number of mutations (Figures 5A,B). This ﬁrst section pro-
vides the MBB with a rapid overview of all detected alterations.
If needed, the MBB can also have access to more detailed results,
with graphical views of the copy number proﬁles for each gene,
as well as the list of mutations with detailed annotation as pre-
viously described (Figures 5C,D). This name-blinded technical
report is sent to the members of the MBB for scientiﬁc validation
and prioritization of the identiﬁed molecular abnormalities.
SUMMARY OF THE DATA INTEGRATION WORKFLOW FOR THE SHIVA
CLINICAL TRIAL WITHIN KDI
In the context of the SHIVA trial, the clinical data needed for the
MBB are ﬁrst imported in a dedicated module of the KDI system,
named ClinicalDB (Clinical Database, Figure 3A). This step is
performed weekly and updates the system by creating the patients
recently included in the trial into the KDI core database. At the
same time, an anonymous identiﬁer is generated by the system
for each new patient. Conversion between the different patient
identiﬁers is guaranteed by the KDI core database and is accessible
through the Bioinfo-Portal web application. Once available, the
raw data generated by the biotechnological platforms are trans-
ferred to the bioinformatics platform for analysis (using rsync
system). Bioinformatics pipelines (mutation and DNA copy num-
ber pipelines) process each molecular proﬁle and are responsible
for raw data storage and traceability within the KDI core database.
The summarized results are structured in the BIRD (Biological
Results Database) application. The last step of the data integra-
tion workﬂow is the generation of the bioinformatics reports. Two
reports are required in the context of the SHIVA clinical trial at
two different time points. A ﬁrst report is generated by the system
after the processing of the DNA copy number proﬁle in order to
request an IHC validation if needed. A second report is gener-
ated by the system and sent to the MBB for the ﬁnal therapeutic
decision. All reports, data and analysis results for each patient
are gathered within the KDI modules (KDI core database, Clini-
calDB, BIRD). All the information are available under controlled
access for any member of the project through the KDI Bioinfo-
Portal. In order to supervise the patients’ process at each step of
the whole bioinformatics workﬂow, an additional module of the
system named the Bioinfo-Board application (Figure 6) has been
developed. This web application aims to controlling, monitoring
and checking the evolution and status of each SHIVA patient in
real-time.
QUALITY MANAGEMENT
Offering a high quality service is most required in the context
of a clinical application. The availability of all KDI’s component
and the reproducibility of the analyses is thus mandatory. To this
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FIGURE 5 | Example of the main features reported in the MBB report.
(A) Patient information. All available clinical and biological informations about
the patient are reported to guide the therapeutic decision. (B) Summary of
molecular abnormalities. DNA copy number and mutations statuses for all
genes are reported in a main table in order to provide a quick overview of the
potential targets. The DNA copy number (D = Deletion, L = Loss,
N = Normal, G = Gain, A = Ampliﬁcation) and the mutations statuses are
color-coded to ease the interpretation. (C) DNA copy number status. For each
gene, detailed informations of their DNA gene copy number and loss of
heterozygosity statuses are provided. The proﬁles are shown for two patients
carrying an ampliﬁcation of EGFR and PDGFRA. (D) Mutation status.
Mutations passing all the ﬁlters are reported as positives mutations. Others
cases can be discussed. In the following example, one variant does not have
any COSMIC ID and has a frequency lower than 10%. Another is annotated
as a recurrent variant, or outside an hotspot region. An IGV screenshot of the
genomic region can help in validating the variant.
aim, we have promoted a set of good practices for the software
building process. First, the software development phase follows
a strict frame with positive technical constraints, and a common
methodology known and shared by each data manager and soft-
ware developer. The conﬁguration management is delegated to a
SVN repository where all the source codes of KDI system are regu-
larly committed. The unit testing is strongly recommended for all
programming languages involved in the system (X-Unit) and part
of our continuous integration server based on Jenkins software.
This system allows to check weekly that all the tests parameterized
for all applications are successfully passed. This control ensures
that the analysis pipelines provide the expected results, identical
to a reference analysis which is considered as a gold standard. Sec-
ond, we pay attention to the availability of KDI system. All web
applications are monitored with Nagios software in order to be
able to detect in real-time any disorder on the system and there-
fore take immediately all necessary actions (log analysis, server
restart, update conﬁguration, etc.) to restore initial and nominal
state if needed.
In order to reach this high quality service expectations,
three different informatics environments (meaning three differ-
ent instances of all applications, three different web servers, three
different database servers and three dedicated ﬁle systems) have
been set up. An update on any environment is always linked with
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FIGURE 6 | Bioinformatics web applications screenshots.
(A) Clinical DB application is dedicated to clinical data storage.
(B) Bioinfo-Board application aims to manage, and monitor each
patient data workﬂow in real-time. (C) Bioinfo-Portal application is
dedicated to the KDI core system database. It allows the access
to all exported data and information for a given patient/project,
such as data or clinical report in the context of the SHIVA
clinical trial.
a SVN revision. The ﬁrst environment is the development (D-
env) which is the place of the version currently in development.
Each developer, after doing unit testing on his local workspace is
allowed to install a new version of his components on this envi-
ronment. It results that the D-env can be temporarily unstable
and this is assumed. The second environment is the validation
(V-env) which must be stable at every time. Integration testing is
performed on this environment to validate the candidate release
of the KDI system. The V-env can be seen as a pre-production
environment. Only the persons in charge of the ﬁnal installa-
tion are allowed to update the V-env. The third environment
is the production (P-env) which is the instance of KDI system
really used by the end-users. The updates of the P-env have to be
planned, secured, and widely announced to avoid any inconve-
nience. During delivery periods, the environments of validation
and production must be identical. These three environments per-
mit to secure our delivery process with a high reliability and
traceability.
FEASIBILITY OF THE SHIVA TRIAL
The presented bioinformatics environment is in use since October
2012 to manage and analyze the molecular proﬁles of the patients
included in the SHIVA trial.
Results of the feasibility part of the project, focused on the
ﬁrst 100 patients were recently published (Le Tourneau et al.,
2014). Among the ﬁrst 100 patients, diagnostic conﬁrmation and
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IHC analyses for hormone receptors were performed in 92% of
the patients. Genomic analyses were performed for 65 patients
(68%). DNA copy number analyses met quality criteria in all the
65 patients, while a technical problem occurred in 2 patients for
mutations analyses. Overall, 58 out of the 95 patients (61%) had a
complete molecular proﬁle. All patient data were integrated in the
KDI system. The median timeframe for the bioinformatics anal-
ysis (DNA copy number, mutation proﬁles and MBB report) was
5 days. Median timeframe from tumor biopsy/resection to MBB
was 26 days [range: 14–42]. To date, eight French cancer centers
are participating to the SHIVA trial, and more than 700 patients
were included. All data provided by the different centers are cen-
tralized at Institut Curie using the KDI system, and analyzed in
routine.
ON-GOING CHALLENGES FOR PM
The solution we have developed to manage the SHIVA clinical trial
provides a ﬁrst step towards the routine application for PM. How-
ever, many challenges still need to be tackled and will require a
lot of mutualization and harmonization efforts within the scien-
tiﬁc community. The main on-going challenges are listed in what
follows.
COMPUTATIONAL ARCHITECTURE
Precision medicine does not only require an efﬁcient informatics
infrastructure at the software level but also at the hardware level.
Indeed, as NGS is now widely used for tumor proﬁling, data pro-
cessing relies on an efﬁcient High Performance Computing (HPC)
infrastructure for data storage, transfer, computation and access
control. So far, mainly targeted sequencing on a limited panel
of genes (e.g., using Ion TorrentTM PGM with AmpliSeqTM) has
been used and can be processed with relatively moderate comput-
ing resources. However, as sequencing cost keeps on decreasing,
whole-exome or even whole-genome might be used soon thus
requiring HPC infrastructure. According to Moore’s law, Kryder’s
law and Butter’s law, costs are halved every 18, 12, and 9 months
for processor, storage and data transfer, respectively (Stein, 2010)
while 5months was the rule for sequencing costs during the period
2007-2011 period (source3). Thus, the difference between biotech-
nological and informatics capacities grows exponentially. Entering
the era of big data in cancer research implies a breakthrough
at the informatics level. First, the scalability of the infrastrure
(Input/Ouput performance and computing power) is required to
allow the management and analysis of ever-growing data. Second,
bioinformaticiansmust be trained to the use of low-level program-
ming languages for parallel computing such as Message Passing
Interface (MPI), Open MultiProcessing (OpenMP), or MapRe-
duce (Dean and Ghemawat, 2008) and to the algorithm analysis.
Developing these new skills will be essential in order to improve
the efﬁciency of software used in downstream analysis to deliver
results as quick as possible to meet deadline expected in the clin-
ical practice. Third, the conﬁguration of job scheduler (such as
Torque/PBS, OGE, or Slurm) must ensure that resources could
be available and allocated to analyze in priority the data needed
for decision-making in clinic. This also implies a redundancy of
3http://www.genome.gov/sequencingcosts/
the hardware components to ensure their availability. Resources
and new know-how are deﬁnitely needed to handle NGS data
and PM. Importantly, the question of which data and how long
the data must be stored is an important issue. We can anticipate
that at some point, the storage capacity will be lower than the
amount of data generated meaning that data will have to be ana-
lyzed on-the-ﬂy to extract the relevant information and reduce the
volume.
EXCHANGE STANDARDS AND ONTOLOGY
The large heterogeneity of the data that are collected along the
healthcare pathway hampered their exchange and their compar-
ison. Therefore, it is crucial to describe all the data that are
generated with controlled vocabularies also called ontologies.
Ontologies offer a formal representation of knowledge with def-
inition of the relevant semantic attributes, their hierarchy and
their relationship using a well-deﬁned logic. Importantly, not
only one single ontology can pretend to describe all the knowl-
edge in a ﬁeld but different ontologies (see4) are necessary to
cover different entities of interest such as the gene (Gene Ontol-
ogy), the disease (Disease Ontology) and the sequence (Sequence
Ontology). Semantic Web standards promoted by World Wide
Web Consortium (W3C) make it possible to link knowledge
and data together so they can be queried and retrieved. To this
aim, the Resource Description Framework (RDF) data format
along with SPARQL query language provide the technical frame-
work to describe, share, interact and query semantic data. While
the technical solutions exist to support data exchange and link-
ing, the deﬁnition of ontology, their choice and their use in
practice for healthcare and biomedical data is still an issue. In
order to tackle these challenges and to promote the use of stan-
dards and ontologies in the biomedical ﬁeld, many European
initiatives supported by the European Community (FP6 and FP7
programs) are involved in the deﬁnition and harmonization of
standards:
1. SemanticHEALTH FP65 focused on semantic interoperabil-
ity issues of electronic health systems and infrastructures
and provided a number of relevant deﬁnitions, stan-
dards, and applicationdomains for semantic interoperability
(Stroetman et al., 2009).
2. SemanticHealthNet FP76 develops a scalable and sustain-
able pan-European organizational and governance process
for the semantic interoperability of clinical and biomedi-
cal knowledge, to ensure that EHR systems are optimized
for patient care, public health and clinical research across
healthcare systems and institutions.
3. p-medicine FP77 aims at developing new tools, data shar-
ing and integration systems, IT infrastructure and Virtual
Physiological Human (VPH) models to accelerate PM for
the beneﬁt of the patient.
Moreover, the European effort BioMedBridges supported by
the European Strategy ForumonResearch Infrastructures (ESFRI)
4http://bioportal.bioontology.org/
5http://www.semantichealth.org
6http://www.semantichealthnet.eu
7http://p-medicine.eu
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aim to construct the data and service bridges needed to connect
emerging biomedical sciences research infrastructures. Among the
infrastructures concerned let us mention:
1. the European Infrastructure for translational medicine:
EATRIS supports the development of biomedical discoveries
for novel preventive, diagnostic or therapeutic products up
to clinical proof of concept.
2. the Biobanking and Biomolecular Resources Research
Infrastructure: BBMRI will form an interface between bio-
logical specimens and data and top-level biological and
medical research.
3. the European Clinical Research Infrastructures Network:
ECRIN supports multinational clinical research projects in
Europe.
4. ELIXIR: (it aims to construct and operate a sustainable
infrastructure for biological information in Europe to sup-
port life science research and its translation to medicine and
the environment, the bio-industries and society.
DEVELOPMENT OF SUSTAINABLE BIOINFORMATICS ANALYSIS
PIPELINES
Maintaining an efﬁcient bioinformatics workﬂow in the context
of PM is today challenging because of the frequent updates of
the computational solutions either installed on the sequencing
machine or provided as standalone applications. These frequent
updates are mainly due to the rapid evolution of the sequencing
andmicroarray technologies but remain amajor issue to ensure the
operability of the bioinformatics pipelines and their reproducibil-
ity. As a consequence, any update requires that each bioinformatics
pipeline is validated to warrant it provides a very high speciﬁcity
and sensitivity. Indeed, any changes in the data format or in the
analysis methods can have critical consequences on the down-
stream analysis and results. Moreover, many different methods
are currently available to analyze NGS data but no consensus or
standard computational tools exist so far. For instance, detecting
germline or somatic mutations can be achieved using different
bioinformatics algorithms, tools and ﬁlters. Choosing the most
efﬁcient algorithm is not an easy task and a feasibility phase is
mandatory to deﬁne which algorithms and parameters to apply
for a dedicated question.
SAMPLE QUALITY CONTROL
The use of high-throughput technology in a clinical context also
offers new challenges in the development of cutting edge sta-
tistical methods and algorithms dedicated to the ﬁeld. As an
example, the integration of heterogeneous molecular proﬁles pro-
vided by microarrays and sequencing assays could be used to
deﬁne a patient genotype signature, to improve molecular pro-
ﬁle accuracy and to ensure that the generated data come from
the same biological samples and patient. The intersection of geno-
type variations available through the SNPs arrays technology could
thus be intersected with the genotype information extracted from
next-generation sequencing. However, this type of quality control
requires the sequencing of a large DNA region to ensure that a
sufﬁcient number of polymorphism is covered. In the same way,
the biopsy cellularity can also be estimated using both microarrays
and sequencing assays (Larson and Fridley, 2013) in order to cor-
relate the tumor purity from both proﬁles and detect intra-tumor
heterogeneity.
DEVELOPMENT OF DEDICATED COMPUTATIONAL AND MATHEMATICAL
METHODS - TOWARDS SYSTEM MEDICINE
Clinical trials for PM rely so far on a very limited number of
biomarkers used for the therapeutic decision (see Simon and Pol-
ley, 2013 for a review). Typically from one up to less than 50
biomarkers are used for PM in currently on-going clinical trials
worldwide. Moreover, the decision is based on a univariate deci-
sion rule meaning that a possible interaction between biomarkers
is not considered which certainly explains part of the limited efﬁ-
cacy of targeted therapies even in the presence of their targets.
For example, Prahallad et al. (2012) showed that vemurafenib is
highly effective in the treatment of melanoma in patients with
BRAF(V600E) mutation while colon cancer patients harboring
the same BRAF(V600E) mutation have a very limited response
to this drug. They found that BRAF normally exerts a negative
feedback regulation of EGFR. Therefore BRAF inhibition causes
a rapid feedback activation of EGFR, which enhances cell prolif-
eration. As melanoma cells express low levels of EGFR they are
not subject to this feedback activation in contrast to colon can-
cer. Thus, they propose that these patients might beneﬁt from
combined therapy consisting of BRAF and EGFR inhibitors. This
example highlights the fact that considering interactions between
biomarkers and combining different therapies together can dra-
matically strengthen the efﬁciency of PM. Also it clearly shows
that elucidating the reasons behind treatment escape and propos-
ing backup therapeutic strategies would beneﬁt greatly from the
knowledge and modeling of the cell regulatory network rewiring.
Therefore, computational systems biology approaches, based on
mathematical models of the cell regulatory network rewiring, are
deﬁnitely needed to deepen our understanding of the cancer cell
and to improve current decision rules. Systems biology and sys-
tems medicine are two disciplines which open the road to PM.
Machine learning techniques will also be very useful to develop
prediction rules to predict outcome and response to treatment.
We can imagine that online machine learning techniques could
be used to reﬁne and optimize decision rules as long as new data
and knowledge are generated. The key deﬁning characteristic of
online learning is that soon after the prediction is made, the true
label of the instance is discovered. This information can then be
used to reﬁne the prediction hypothesis used by the algorithm.
In the case of cancer, every day, for several patients, informa-
tion is collected: survival, response to therapy, molecular proﬁles,
pathological complete response, etc. This information could be
used to retrain the classiﬁer on the available data. In addition to
these data-driven approaches, knowledge-based approaches must
be developed to capitalize on the large amount of knowledge that
is present in the scientiﬁc and medical literature to build efﬁcient
decision rules. IBM has developed a supercomputer named Wat-
son (the name of IBM’s founder) able to understand question in
natural language and to extract relevant information from the lit-
erature. Watson supercomputer is currently used at the Memorial
Sloan-Kettering (New-York, USA) to help for diagnosis in lung
cancer.
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SEQUENCING THE GENOME AND BEYOND
Available NGS techniques expand from sequencing panels based
on a couple of genes to whole-exome and whole-genome sequenc-
ing. Even if the whole-exome and whole-genome sequencing are
currently used in cancer research, and can be seen as the future
of the clinical investigation, their use in routine clinical prac-
tice is much more difﬁcult, mainly because the average depth of
coverage is much lower than for targeted genes sequencing com-
plicating mutations detection. However, these applications offer
new ways to explore DNA copy number and structural variations
and can thus be used as an alternative to the current microar-
ray technologies. In addition, the current sequencing capabilities
also offer new opportunities to develop gene/transcript expres-
sion and epigenomics biomarkers in clinic. For instance, the
detection of BRCA1/BRCA2 isoforms and their quantiﬁcation
using RNA-seq approach would be an interesting complemen-
tary approach to mutations screening. In the same way, DNA
methylation, histone modiﬁcations, small non-coding regulatory
RNAs, or nucleosome remodeling regulate many biological pro-
cesses involved in tumorigenesis. More recently, evidence that
genetic and epigenetic mechanisms are related events in cancer
has emerged. Alteration in epigenetic mechanisms can lead to
somatic mutations, as well as somatic mutations in epigenetic reg-
ulators can lead to an altered epigenome (You and Jones, 2012;
Timp and Feinberg, 2013). If drug discovery in cancer epigenetics
had been held back due to concern about speciﬁcity and toxic-
ity, it remains an active ﬁeld of investigation (see Dawson and
Kouzarides, 2012, for a review). The application of these new
ﬁelds in clinic raises the question of combined therapies. Com-
bination of targeted therapy with chemotherapy or with other
targeted therapies is challenging because of increased toxicity.
Solutions include the use of lower doses of drugs which might
not be relevant if the biologically active dose is not reached and
the use of drugs in a sequential manner although the relevance
of this approach still needs to be demonstrated. For instance, it
is likely that the combination of standard chemotherapy together
with drugs against mutated proteins and epigenetics drugs offer
synergetic beneﬁts and increase therapeutic efﬁcacy. Integrative
analysis considering the multidimensional nature of the cancer
(genome, proteome, epigenome, kinome, etc.) is therefore a major
challenge to unravel the complexity of the disease and identify the
most efﬁcient treatments. To this aim, we will have to capitalize
on large collection of public datasets such as data from The Can-
cer Genome Atlas (TCGA8, Kandoth et al., 2013) or International
Cancer Genome Consortium (ICGC9) and also pathway databases
for gene regulatory network, signaling pathway, metabolic path-
way, Protein-Protein Interaction network and protein-compound
network (e.g., DIP, HPRD, KEGG, Reactome to name only a few).
The TCGA has initiated a pan-cancer analysis project (Cancer
Genome Atlas Research Network et al., 2013) on the ﬁrst 12 tumor
types proﬁled by the consortium where the goal is to characterize
molecular alterations and their functional impact across tumor
type in order to promote the development of new therapies to
ﬁght cancer.
8http://cancergenome.nih.gov/
9http://icgc.org/
CONCLUSION
Wehave developed a seamless information systemnamedKDI that
fully supports the essential bioinformatics requirements for PM.
The system allows management and analysis of clinical informa-
tion, classical biological data as well as high-throughput molecular
proﬁles. It can deliver in real-time information to be used by
the medical and biological staff for therapeutic decision-making.
KDI makes it possible to share information and communicate
reports and results across numerous stakeholders, representing
a large continuum of expertise from medical, clinical, biologi-
cal, translational, technical and biotechnological know-hows. The
system relies on state-of-the-art informatic technologies allow-
ing cross-software interoperability, automatic data extraction,
quality control and secure data transfer. KDI has been suc-
cessfully used in the framework of the SHIVA clinical trial for
more than 18 months. KDI is also currently used for other
clinical trials supported by European Union consortia covering
cancer (RAIDs - Rational molecular Assessments and Innovative
Drugs selection in cervival cancer) and non-cancer applications
(MAARS - Microbes in Allergy and Autoimmunity Related to the
Skin). This demonstrates the potentiality and ﬂexibility of our
system to support PM covering all its requirements ranging from
data management, data traceability, data analysis, query, and
visualization.
The evolution of sequencing technologies has expanded the
frontiers of genomics in both biology and clinical environments.
The sequencing ﬁeld will continue to evolve rapidly, offering
lower costs and increased speeds. On-going developments in
the sequencing technology, such as an ultrafast sequencer like
nanopore technology, will improve performance and miniatur-
ization, thus offering new tools to improve prevention, diagnosis,
prognosis, choice of the treatment and follow-up for patients in
oncology. To promote PM in daily clinical routine, ﬂexible bioin-
formatics systems like KDI are deﬁnitely required for enabling
efﬁcient sharing of information in real-time, and rapid data pro-
cessing needed for therapeutic decisions. KDI also provides the
infrastructure for developing and integrating into the clinical deci-
sion process new integrative analysis methods with sophisticated
mathematical models, representing the multidimensional nature
of cancer to propose new biomarkers and to develop new therapies
to ﬁght cancer.
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